Jubilant Therapeutics names Daniel O'Connor chief executive

Jubilant Pharmova Limited announced the appointment of Daniel J. O'Connor as the chief executive officer of Jubilant Therapeutics Inc., a step-down subsidiary. This appointment, effective December 1, 2025, aims to bolster the company's proprietary novel drugs business.

O'Connor brings over 30 years of leadership experience in biotechnology and oncology, with a focus on creating value through differentiated, IP-rich platforms. His previous roles include chief executive of Ambrx Biopharma, where he significantly increased company valuation, and instrumental positions at ImClone Systems, contributing to clinical development and commercialization of oncology therapies. He also served as chief executive of Advaxis, transforming it into a late-stage clinical enterprise.

Jubilant Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing precision oral medicines for oncology and autoimmune diseases. Its pipeline includes JBI-802, a dual COREST modifier in Phase I/II trials, and a novel brain-penetrant modulator of PRMT5 also in Phase I clinical trials. The company also has preclinical programs for PDL1 and PAD4 inhibitors.